We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+31.25%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.67B
AUM Growth
+$753M
Cap. Flow
-$209M
Cap. Flow %
-7.82%
Top 10 Hldgs %
54.38%
Holding
380
New
93
Increased
88
Reduced
106
Closed
73

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.1M
2
CYTR
CytRx Corp
CYTR
+$5.67M
3
CELG
Celgene Corp
CELG
+$4.08M
4
UTHR icon
United Therapeutics
UTHR
+$3.38M
5
DVAX
Dynavax Technologies
DVAX
+$3.33M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$7.47M
2
ABT icon
Abbott
ABT
+$6.5M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.84M
4
NVIV
InVivo Therapeutics Holdings Corp
NVIV
+$3.87M
5
AMGN icon
Amgen
AMGN
+$3.54M

Sector Composition

Rank Sector Weight
1 Healthcare 9.24%
2 Consumer Staples 0.04%
3 Technology 0.03%
4 Industrials 0.01%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
126
CALL
Insmed
INSM
$22.4B
$2.12M 0.08%
1,459
+113
+8% +$1.42K
SGYPW
127
PUT
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$2.12M 0.08%
+3,842
New +$2.32K
FWP
128
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.08M 0.08%
14,150
-441
-3% -$62.1K
VNDA icon
129
CALL
Vanda Pharmaceuticals
VNDA
$304M
$2.08M 0.08%
1,247
-143
-10% -$1.93K
IOVA icon
130
Iovance Biotherapeutics
IOVA
$2.04B
$2.03M 0.08%
246,342
-120,900
-33% -$1.02M
IRD
131
Opus Genetics
IRD
$287M
$1.99M 0.07%
19,718
+820
+4% +$99.1K
PRTA icon
132
CALL
Prothena Corp
PRTA
$448M
$1.95M 0.07%
+325
New +$17.4K
ATNM icon
133
Actinium Pharmaceuticals
ATNM
$26.3M
$1.87M 0.07%
+46,088
New +$2.37M
FOMX
134
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.87M 0.07%
201,564
-52,142
-21% -$436K
BDSI
135
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.86M 0.07%
689,900
-95,899
-12% -$244K
BPTH
136
DELISTED
Bio-Path Holdings Inc
BPTH
$1.84M 0.07%
329
-418
-56% -$2.68M
EDIT icon
137
Editas Medicine
EDIT
$399M
$1.82M 0.07%
+135,000
New +$2.77M
INSM icon
138
PUT
Insmed
INSM
$22.4B
$1.81M 0.07%
1,247
+476
+62% +$5.96K
AGEN
139
PUT
Agenus
AGEN
$276M
$1.79M 0.07%
+127
New +$14.6K
NTLA icon
140
Intellia Therapeutics
NTLA
$1.51B
$1.78M 0.07%
+104,841
New +$2.03M
ACHC icon
141
PUT
Acadia Healthcare
ACHC
$2.55B
$1.74M 0.07%
+548
New +$28.5K
ZGNX
142
DELISTED
Zogenix, Inc.
ZGNX
$1.72M 0.06%
150,000
-139,200
-48% -$1.28M
AIM
143
AIM ImmunoTech
AIM
$6.65M
$1.69M 0.06%
+308
New +$2.16M
FOLD
144
PUT
DELISTED
Amicus Therapeutics
FOLD
$1.69M 0.06%
2,282
+48
+2% +$324
NVRO
145
CALL
DELISTED
NEVRO CORP.
NVRO
$1.68M 0.06%
+161
New +$14.5K
GBT
146
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.66M 0.06%
721
+300
+71% +$5.72K
ADVM
147
DELISTED
Adverum Biotechnologies
ADVM
$1.66M 0.06%
40,260
-37,733
-48% -$1.43M
FOCL
148
EDAP TMS S.A.
FOCL
$234M
$1.58M 0.06%
545,918
-301,307
-36% -$919K
CYTXW
149
DELISTED
Cytori Therapeutics Inc Warrant
CYTXW
$1.55M 0.06%
895,017
-109,048
-11% -$90.4K
CORV
150
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$1.52M 0.06%
+484,505
New +$1.77M
4 5
6
7 8

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sabby Management held 380 positions worth $2.67B, up 39% from $1.92B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sabby Management withdrew a net $209M in Q3 2016, closing 73 positions and reducing 106 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $4.84M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, down from 13% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Sabby Management opened a new position in Bristol-Myers Squibb worth $8.46M.

  • Sabby Management's largest Q3 2016 buy was Bristol-Myers Squibb: 156,887 shares worth $8.46M.
  • Sabby Management added most to Dynavax Technologies in Q3 2016, an estimated $3.33M increase.
  • Sabby Management's biggest Q3 2016 reduction was Sarepta Therapeutics, cutting an estimated $7.47M.
  • Sabby Management fully exited Global Blood Therapeutics, Inc. in Q3 2016, selling an estimated $4.84M.
  • Sabby Management's ten largest holdings make up 54% of its $2.67B portfolio in Q3 2016.
  • Sabby Management opened 93 new positions and closed 73 in Q3 2016.
  • Sabby Management's portfolio value rose 39% quarter-over-quarter to $2.67B.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.